Medicare spending analysis for Mass Immunizer Roster Biller providers
Mass Immunizer Roster Biller accounts for $6.0B in Medicare payments across 233.9K providers.
The specialty's average markup of 1.2x is below the overall Medicare average of 3.77x.
AI-generated analysis based on Medicare payment data.
| Year | Payments | Services | Providers | YoY Change |
|---|---|---|---|---|
| 2016 | $302.1M | 8.0M | 29.7K | — |
| 2017 | $344.6M | 9.0M | 30.1K | +14.1% |
| 2018 | $372.2M | 9.5M | 29.2K | +8.0% |
| 2019 | $398.1M | 10.2M | 28.4K | +7.0% |
| 2020 | $499.3M | 12.5M | 28.2K | +25.4% |
| 2021 | $1.4B | 40.4M | 30.3K | +180.2% |
| 2022 | $1.2B | 46.8M | 29.7K | -14.7% |
| 2023 | $1.5B | 37.6M | 28.3K | +25.4% |
| Code | Description | Payments | Services | Avg/Service |
|---|---|---|---|---|
| 91322 | Sarscov2 vac 50 mcg/0.5ml im | $302.0M | 2.1M | $142.80 |
| 91320 | Sarscv2 vac 30mcg trs-suc im | $215.5M | 1.7M | $128.39 |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | $203.7M | 18.7M | $10.88 |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | $195.8M | 2.6M | $74.65 |
| 90480 | Admn sarscov2 vacc 1 dose | $138.3M | 3.8M | $36.14 |
| G0008 | Administration of influenza virus vaccine | $133.7M | 4.8M | $27.71 |
| 90662 | Influenza vaccine split virus, preservative free | $132.1M | 1.9M | $70.33 |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | $123.9M | 443.3K | $279.53 |
| 0124A | Adm sarscv2 bvl 30mcg/.3ml a | $16.9M | 410.2K | $41.28 |
| 0134A | Adm sarscv2 bvl 50mcg/.5ml a | $16.6M | 401.4K | $41.42 |
| G0009 | Administration of pneumococcal vaccine | $8.6M | 448.0K | $19.27 |
| 90686 | Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | $1.8M | 84.3K | $21.58 |
| 90674 | Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free | $1.5M | 46.2K | $32.84 |
| 0241U | Respiratory infectious agent detection by rna for severe acute respiratory syndrome coronavirus 2 (covid 19), influenza a, influenza b, and respiratory syncytial virus, upper respiratory specimen, each reported as detected or not detected | $753.3K | 5.4K | $139.78 |
| 90682 | Influenza vaccine, quadrivalent derived from recombinant dna | $745.6K | 10.7K | $69.77 |
| M0201 | Covid-19 vaccine administration inside a patient's home; reported only once per individual home per date of service when only covid-19 vaccine administration is performed at the patient's home | $737.7K | 20.4K | $36.14 |
| 0121A | Adm sarscv2 bvl 30mcg/.3ml 1 | $495.9K | 11.4K | $43.36 |
| 91304 | Severe acute respiratory syndrome coronavirus 2 (covid-19) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5ml dosage, for intramuscular use | $424.3K | 3.0K | $140.63 |
| 90732 | Pneumococcal vaccine, 23-valent | $376.9K | 2.9K | $130.74 |
| 90688 | Influenza vaccine, quadrivalent, 0.5 ml dosage | $244.3K | 12.1K | $20.26 |
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.